Transgene Biotek Limited , a biotechnology company, has announced its financial results for the quarter ended September 30, 2025, along with several significant board decisions. The company's performance and corporate actions indicate ongoing challenges and strategic moves.

Financial Performance

Transgene Biotek reported a net loss of Rs. 38.84 lakhs for the quarter ended September 30, 2025. This loss comes despite a modest revenue from operations of Rs. 5.28 lakhs for the same period. The company's total expenses for the quarter stood at Rs. 44.12 lakhs, significantly outweighing its income.

Key Financial Metrics

The company's financial position remains challenging, with the balance sheet showing a negative 'Other Equity' of Rs. 8,413.90 lakhs as of September 30, 2025.

Board Approvals and Corporate Actions

In a board meeting held on November 14, 2025, Transgene Biotek's directors made several key decisions:

1. Annual General Meeting (AGM): The company's 35th AGM is scheduled for December 30, 2025, to be held through video conferencing.

2. Director Reappointments: The board approved the following reappointments, subject to shareholder approval:

   • Dr. K. Koteswara Rao as Chairman & Managing Director for one year
   • Mrs. Sujana Kadiam, Mr. Santhosh Kumar, and Mrs. Swetha Marri as Independent Directors, each for a five-year term

3. E-voting: The company appointed Mrs. Geeta Servani as the scrutinizer for e-voting, with the remote e-voting period set from December 27 to December 29, 2025.

4. Book Closure: The Register of Members and Share Transfer Books will remain closed from December 24 to December 30, 2025.

Ongoing Legal Challenges

Transgene Biotek continues to face legal hurdles that may impact its operations:

1. The matter at the Securities Appellate Tribunal (SAT) in Mumbai is ongoing, with the next hearing scheduled for January 9, 2026.
2. A hearing at the Appellate Tribunal in New Delhi is set for January 5, 2026.
3. The company is addressing an appeal filed by Babaji Nethralayya at the National Company Law Tribunal (NCLT) Hyderabad bench.

These legal proceedings, coupled with the company's financial performance, underscore the challenges Transgene Biotek is currently navigating.

Looking Ahead

As Transgene Biotek grapples with financial losses and legal issues, the reappointment of key directors suggests a focus on maintaining leadership continuity. The company's ability to address its financial challenges and resolve ongoing legal matters will likely be crucial for its future prospects.

Transgene Biotek , a biotechnology company based in Telangana, India, is currently facing a legal challenge at the National Company Law Tribunal (NCLT) in Hyderabad. The case, filed by Babaji Nethralayya Private Ltd, concerns an unpaid loan amount of Rs 6.82 crore along with interest and other charges.

Key Details of the Legal Case

Company's Response

In a filing to the Bombay Stock Exchange (BSE) dated October 16, 2025, Transgene Biotek acknowledged the legal proceedings. Dr. K. Koteswara Rao, the Managing Director of Transgene Biotek, stated in the declaration that the company is "making efforts to resolve this matter amicably as per the required urgency."

The case highlights the financial challenges that Transgene Biotek is currently facing. While the company has not provided specific details about the origin or terms of the loan, the substantial amount involved suggests it could have a significant impact on the company's financial position.

Investors and stakeholders will be closely watching the developments of this case, as its outcome could have implications for Transgene Biotek's future operations and financial stability. The next hearing, scheduled for December 16, 2025, may provide more clarity on the situation and potential resolutions.

It's important to note that legal proceedings of this nature can be complex and may take time to resolve. The company's stated intention to seek an amicable resolution indicates a willingness to address the issue outside of the court system, which could potentially lead to a faster resolution.

As this situation develops, shareholders and potential investors should stay informed about any further updates from the company or the NCLT proceedings.